Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus MUCINEX D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX D 12 HOUR versus MUCINEX D.
CLARINEX-D 12 HOUR vs MUCINEX D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Mucinex D contains guaifenesin, which is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity and enhance mucus clearance, and pseudoephedrine, a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
Mucinex D contains guaifenesin 600 mg and pseudoephedrine 60 mg per extended-release tablet. Usual adult dose: 1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
Guaifenesin: 1 hour (short t½, requires frequent dosing). Pseudoephedrine: 5-8 hours (prolonged with alkaline urine)
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Guaifenesin: Renal (primarily as metabolites, <5% unchanged). Pseudoephedrine: Renal (70-90% unchanged, dependent on urine pH)
Category C
Category C
Antihistamine/Decongestant Combination
Expectorant/Decongestant Combination